Novo Nordisk is the drug company that makes Wegovy and Ozempic.

诺和诺德是生产Wegovy和Ozempic的制药公司。

Another drug made by Novo Nordisk, Wegovy, is a weekly injection.

诺和诺德公司生产的另一种药物Wegovy是每周注射一次。

The drug, made by Novo Nordisk, is set to come off patent soon.

该药物由诺和诺德公司生产，专利即将到期。

Our contributor Sara Reardon also reached out to Novo Nordisk and Eli Lilly.

我们的投稿人 Sara Reardon 还联系了诺和诺德和礼来公司。

The process of turning carbs into fat is called de novo lipogenesis.

将碳水化合物转换成脂肪的过程叫脂质新生。

The SREBP1 from before activates these three enzymes to start a process called de novo lipogenesis.

之前那个 SREBP1 会激活这三个酶，启动一个名为脂肪酸合成的过程。

Novo is mainly working toward Wegovy's launch in the United States and other wealthy markets.

诺和诺德公司主要在美国和其他富裕市场推出Wegovy。

Aleks Engel of Novo Holdings, another asset manager, cites this model as a perennial gripe among fellow investors in antibiotics.

另一名资产经理，Novo Holdings的亚历克斯·恩格尔把这种模式看做是抗生素投资者常年的抱怨。

Novo Nordisk is their new port of call.

诺和诺德是他们的新停靠港。

Eli Lilly, Novo Nordisk and Sanofi should answer our calls for transparency.

礼来、诺和诺德和赛诺菲应该响应我们对透明度的呼吁。

So this Novo study was a late stage clinical trial of its obesity drug, Wegovy.

因此，Novo 的这项研究是其肥胖药物 Wegovy 的后期临床试验。

Sanofi, Eli Lilly and Novo Nordisk, control nearly 96 percent of the world's insulin supply.

赛诺菲、礼来和诺和诺德控制着全球近 96% 的胰岛素供应。

Novo Nordisk said in a statement it was not involved in the request to consider liraglutide for the WHO list.

诺和诺德公司在一份声明中表示，它没有提出考虑将利拉鲁肽列入世卫组织清单的请求。

Fructose forms something called Xylulose 5-Phosphate, and this further stimulates the de novo lipogenesis enzymes, leading to even more fat making.

果糖会形成一种叫木酮糖-5-磷酸的东西这东西会进一步刺激“新脂肪酸合成”这个人体机制，导致更多的脂肪的生成。

Instead of buying insulin from big pharmaceutical companies such as Eli Lilly, Novo Nordisk, they want to make their own insulin.

他们不想从礼来、诺和诺德等大型制药公司购买胰岛素，而是想自己制造胰岛素。

Findings of a late stage trial for Novo Nordisk's weight loss drug came out yesterday.

诺和诺德减肥药的后期试验结果昨天公布。

In the eyes of some pundits, Novo has flubbed its lead.

在一些权威人士看来，Novo 失去了领先优势。

Novo Nordisk, a Danish pharmaceutical giant, is one of the firms trying to make medicines using miRNAs.

丹麦制药巨头诺和诺德公司是尝试利用 miRNA 生产药物的公司之一。

Investors also drove up Novo's share price by about 18 per cent yesterday.

昨天，投资者还推高了 Novo 股价约 18%。

With semaglutide in short supply, Novo has had to push back the oral version's launch.

由于索马鲁肽供应短缺，诺和诺德不得不推迟口服版本的上市。